

IN THE CLAIMS:

Please amend the claims as follows:

Claims 1-9 (**cancelled**).

Claim 10 (**original**): A pharmaceutical composition which comprises AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a taxane in association with a pharmaceutically acceptable excipient or carrier.

Claim 11 (**original**): A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof and a taxane.

Claim 12 (**currently amended**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a taxane.

Claim 13 (**currently amended**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a taxane and before, after or simultaneously with an effective amount of ionising radiation.

Claim 14 (**currently amended**): ~~The~~ A-method according to any one of claims 12, 13, 17 and 18 ~~claim 12 or claim 13~~ wherein AZD2171 is in a form of the free base.

Claim 15 (**currently amended**): ~~The~~ A-method according to any one of claims 12, 13, 17 and 18 ~~12-14~~ wherein the taxane is paclitaxel.

Claim 16 (**currently amended**): The A-method according to any one of claims 12, 13, 17 and 18-12-14 wherein the taxane is docetaxel.

Claim 17 (**new**): A method for treating a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a taxane.

Claim 18 (**new**): A method for treating a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a taxane and before, after or simultaneously with an effective amount of ionising radiation.